
PBH Stock Forecast & Price Target
PBH Analyst Ratings
Bulls say
Prestige Consumer Healthcare is experiencing a robust upward trend in its financial outlook, evidenced by an increased EBITDA estimate for 2026 and 2027 by approximately $15 million due to anticipated sales growth. The company is expected to see significant organic volume growth, particularly in Specialty Foods, driven by an acceleration in new product launches and a positive same-store sales performance, notably with a notable increase in September and continuing into October. Furthermore, Prestige's focus on operational efficiencies and reduced input costs could lead to greater-than-expected EBITDA margin expansion, positioning the company for enhanced free cash flow growth and stronger consumer spending in the U.S. market.
Bears say
Prestige Consumer Healthcare faces a negative outlook primarily due to anticipated lower-than-expected revenue growth, combined with EBITDA margin compression driven by persistent increases in input costs. The company is also experiencing challenges in its key markets, which could lead to weaker operating performance from its largest customers. Additionally, potential risks include a lack of acquisition opportunities and the possibility of divesting non-core assets, which could affect its financial leverage and free cash flow.
This aggregate rating is based on analysts' research of Prestige Brands Holdings and is not a guaranteed prediction by Public.com or investment advice.
PBH Analyst Forecast & Price Prediction
Start investing in PBH
Order type
Buy in
Order amount
Est. shares
0 shares